Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0O3QI
|
|||
| Former ID |
DNC012030
|
|||
| Drug Name |
Benzo[1,3]dioxol-5-ylmethyl-quinazolin-4-yl-amine
|
|||
| Synonyms |
CHEMBL66732; Benzo[1,3]dioxol-5-ylmethyl-quinazolin-4-yl-amine; SCHEMBL5137740; MolPort-007-049-029; ZINC12360740; BDBM50038983; AKOS002366252; MCULE-7168990543
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H13N3O2
|
|||
| Canonical SMILES |
C1OC2=C(O1)C=C(C=C2)CNC3=NC=NC4=CC=CC=C43
|
|||
| InChI |
1S/C16H13N3O2/c1-2-4-13-12(3-1)16(19-9-18-13)17-8-11-5-6-14-15(7-11)21-10-20-14/h1-7,9H,8,10H2,(H,17,18,19)
|
|||
| InChIKey |
MLVNLAHRZDXSAM-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Phosphodiesterase 5A (PDE5A) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Purine metabolism | |||
| cGMP-PKG signaling pathway | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Reactome | cGMP effects | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Cyclic GMP phosphodiesterase inhibitors. 2. Requirement of 6-substitution of quinazoline derivatives for potent and selective inhibitory activity. J Med Chem. 1994 Jun 24;37(13):2106-11. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.